User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6039

Interactions with Platform & by Email *

INTERACTIONS

966

Unique # Participated *

PARTICIPANTS

181

Responses Validated *

VALIDATIONS

39

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Apoptosis: A Natural Part of Cell Lifecycle.....II-4
The Cell Death Pathway: A Review.....II-4
1$100
   Apoptosis Modulating Drugs All Set for Commercial Stage Competition.....II-5
Table 1: Apoptosis Drugs Pipeline Scenario Worldwide (2008): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Development Stage (includes corresponding Graph/Chart).....II-5
1$350
   R&D Scenario.....II-6
Table 2: Apoptosis R&D Scenario Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Treatment Area (includes corresponding Graph/Chart).....II-6
1$350
   Table 3: Apoptosis Drug Development Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Agent Type (includes corresponding Graph/Chart).....II-7

Table 4: Top Nations for Apoptosis Research (2011): Breakdown of Number of Researchers Involved in Apoptosis Research by Country (includes corresponding Graph/Chart).....II-7
1$350
   Popular Classes of Molecules Influencing the Apoptotic Process: A Review.....II-8
Noteworthy Molecular Targets for Apoptosis.....II-8
Death Receptors.....II-8
Caspases.....II-8
IAPs and SMAC.....II-8
Bcl-2 proteins.....II-8
1$100
   p53.....II-9
Table 5: Apoptosis Drugs Pipeline Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Agents in Development by Molecular Target.....II-9
1$350
   HSP90: A Popular Gene Target for Apoptosis.....II-10
Apoptosis: The Key to Cutting Edge Cancer Treatment/Therapies.....II-10
1$100
   Table 6: Apoptosis R&D in Cancer Treatment (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Type of Cancer (includes corresponding Graph/Chart).....II-11
Focus on Targeted Therapy Bodes Well for Apoptosis-Targeted Therapies for
  Cancer.....II-11
1$350
   Overcoming Therapy/Drug Resistance: A Major Business Case for Direct
  Apoptogens.....II-12
Factors Encouraging Investments in Apoptosis Based Cancer Drugs.....II-12
Rise in Cancer Incidences Fosters Growth in Cancer Related Apoptosis
  Research.....II-12
1$100
   Low Entry Barriers in Cancer Research Encourages Cancer Related Apoptosis
  Research.....II-13
Government Funded Investments Bode Well for Cancer Related Apoptosis
  Research.....II-13
High Prices/Efficacy Encourage Pharmas in Pushing Commercialization of
  Apoptosis-Based Anticancer Drugs.....II-13
1$100
   Kinase Inhibitors: Cutting Edge Second Generation of Indirect Apoptogens.....II-14 1$100
   Table 7: World Market for Kinase Inhibitors (2010): Breakdown of Sales (In US$ Million) of Key Kinase Inhibitor Drugs (includes corresponding Graph/Chart).....II-15
Outlook.....II-15
1$350
   Apoptosis: Definition.....II-16
Importance of Apoptosis.....II-16
1$100
   Apoptosis Mechanism.....II-17
Execution of Apoptosis.....II-17
1$100
   Dead Cell Removal.....II-18
Apoptosis & Diseases.....II-18
Faulty Apoptotic Pathways.....II-18
Cancer.....II-18
Non-Cancer Diseases.....II-18
1$100
   Neurodegeneration.....II-19
Liver Diseases.....II-19
Heart Diseases.....II-19
Autoimmune Diseases.....II-19
1$100
   Categories of Apoptogens in the Marketplace.....II-20
First Generation Indirect Apoptogens (IAs).....II-20
Second Generation Indirect Apoptogens (IAs).....II-20
Direct Apoptogens.....II-20
How Apoptosis is Targeted in Disease Research .....II-20
Role of Death Receptors in Apoptosis.....II-20
1$100
   TNF Receptor Signaling.....II-21
Signaling by Fas (CD95).....II-21
Apoptosis Induction by TRAIL.....II-21
Caspase Inhibitors & Activators.....II-21
1$100
   Role of Intrinsic (Mitochondrial) Death Pathways in Apoptosis.....II-22
Bcl-2 Family Proteins.....II-22
1$100
   Targeting Mitochondria Directly.....II-23
Role of IAPs (inhibitors of apoptosis proteins) in Apoptosis Regulation.....II-23
Tumor Suppressor p53.....II-23
2$125
   Cleveland BioLabs Pre-Clinical Data Demonstrates Anticancer Effect of CBLB502.....II-25
Senesco Technologies Files for IND for SNS01-T.....II-25
Celgene Corporation Receives FDA approval for Priority Review of sNDA for
  ISTODAX®.....II-25
IntelliCyt Introduces a Suite of Assay Kits for Apoptosis Screening.....II-25
1$100
   Vitamin E Tocotrienol Found to Increase Cancer Cell Apoptosis Without Toxicity.....II-26
Protectan Technology May Lead to Drugs That Mitigate Effects of Radiation
  Exposure.....II-26
VisEn Partners with MosaMedix to Introduce Annexin-Vivo 750 Imaging Agent for
  Monitoring Programmed Cell Death.....II-26
AnaSpec Introduces Z-Fish Antibodies.....II-26
1$100
   Rexahn Pharmaceuticals Publishes Preclinical ResearchData of Quinoxalinyl-Piperazine
  Compounds.....II-27
Aegera Therapeutics Completes the Phase I Study of AEG35156/Sorafenib
  Combination.....II-27
Amgen Announces Phase II Results of Clinical Studies of AMG 479.....II-27
ArQule Announces Commencement of Phase II trial of ARQ 197 by Kyowa Hakko
  Kirin.....II-27
1$100
   ArQule Announces Daiichi Sankyo Plans to Move Ahead with Phase III clinical trial of
  ARQ 197.....II-28
Celgene International Releases the Phase II Trial Data of ISTODAX® in Treatment of
  PTCL.....II-28
Romidepsin (FK228/depsipeptide) Successfully completes Phase I clinical Trial.....II-28
S*BIO Announces Results of Phase I trial for SB939 for Hematologic
  Malignancies.....II-28
1$100
   EntreMed Publishes the Phase II Pre Clinical Results of ENMD-2076.....II-29
Eli Lilly Concludes Phases II trials for LY2181308 in Myeloid Leukaemia.....II-29
Abbott to Present Data On Four Investigational Compounds.....II-29
Can-Fite BioPharma to Commence the Phase I/II Clinical Trial with CF102.....II-29
TetraLogic Announces Inclusion of Pfizer Ventures into the Series C Investors
  Syndicate.....II-29
1$100
   DiaTech Oncology Files Patent for MiCK (Microculture Kinetic) Assay.....II-30
Gloucester Pharma Intends to Discuss About New Drug Application for Romidepsin.....II-30
Cleveland BioLabs, Inc. Receives First Patent In the US.....II-30
Daiichi Sankyo Commences Phase II Clinical Trials of CS-1008.....II-30
1$100
   Cephalon to Take Over Gemin X.....II-31
Amarantus BioSciences Enters into Licensing Agreement with Generex
  Biotechnology.....II-31
Celgene Takes Over Gloucester Pharmaceuticals.....II-31
1$100
   Sanofi Signs Research and Development Agreement with Ascenta.....II-32
BIOCIUS Life Sciences Collaborates with BlueSky Biotech for Providing Validated
  Enzymes.....II-32
Ascenta Therapeutics Signs Agreement with Leukemia & Lymphoma Society.....II-32
1$100
   Ascenta Therapeutics Collaborates with Ascentage Pharma Group.....II-33
Aposense and Roche Ink Collaboration Agreement.....II-33
Conatus Takes Over Idun.....II-33
Cancer Research Technology Enters into Licensing Deal with ValiRx.....II-33
1$100
   Scancell Holdings Signs Licensing Agreement with University of Nottingham.....II-34
D-Pharm Collaborates with Wanbang Biopharmaceuticals.....II-34
ACEA Biosciences, Roche and Vivo Biosciences Enter into Collaboration.....II-34
1$100
   Infinity and Mundipharma Enter Into Global Alliance.....II-35
Sigma-Aldrich and Highlands Stable Isotope Corporation Enter into an Agreement.....II-35
EntreMed, Inc. Enters Into Security Purchase Agreement with Group of Strategic
  Investors.....II-35
IBA Signs Collaboration Agreement with Aposense.....II-35
1$100
   Clinical Data and CombinatoRx Sign Partnership and Licensing Agreement.....II-36
FASgen and Centocor Ink Research and License Agreement.....II-36
Graceway Pharmaceuticals Obtains Global Right forGS9191 Molecule.....II-36
1$100
   Æterna Zentaris Signs an Agreement with Sanofi-Aventis.....II-371$100
   Abbott Laboratories (USA).....II-38
AbGenomics International, Inc. (USA).....II-38
Aegera Therapeutics, Inc. (Canada).....II-38
Amgen, Inc. (USA).....II-38
1$100
   Anavex Life Sciences Corporation (USA).....II-39
ApopLogic Pharmaceuticals Inc. (USA).....II-39
Ascenta Therapeutics (USA).....II-39
ArQule, Inc. (USA).....II-39
1$100
   Bioniche Life Sciences, Inc. (Canada).....II-40
Celgene Corporation (USA).....II-40
Chroma Therapeutics Ltd (UK).....II-40
Cancer Research Technology Ltd. (UK).....II-40
1$100
   EntreMed, Inc. (USA).....II-41
EpiCept Corporation (USA).....II-41
Exelixis Inc. (USA).....II-41
Genextra S.p.A. (Italy).....II-41
Genta, Inc. (USA).....II-41
1$100
   Infinity Pharmaceuticals Inc. (USA).....II-42
ISIS Pharmaceutical Inc. (USA).....II-42
Novartis Ltd. (Switzerland).....II-42
Pfizer, Inc. (USA).....II-42
1$100
   Pharmacyclics, Inc. (USA).....II-43
S*BIO Pte Ltd. (Singapore).....II-43
Theraptosis SA (France).....II-43
TopoTarget A/S (Denmark).....II-43
1$100
   Xigen SA (Switzerland).....II-44
Æterna Zentaris GmbH (Germany).....II-44
1$100
   Table 8: World Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-451$350
   Table 9: World Historic Review for Apoptosis Modulators in Oncology by Region/Country - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-461$350
   A. Market Analysis.....II-47
Current & Future Analysis.....II-47
Overview.....II-47
High Incidence of Pancreatic Cancer Drives Demand for Apoptosis Modulators in
  US Market.....II-47
Drug Approvals, Introductions & Clinical Trials.....II-47
3$175
   Recent Industry Activity.....II-503$175
   Key Players.....II-534$175
   B. Market Analytics.....II-57
Table 10: US Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-57
1$350
   Table 11: US Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-581$350
   A. Market Analysis.....II-59
Current & Future Analysis.....II-59
Clinical Trials.....II-59
Recent Industry Activity.....II-59
Key Players.....II-59
1$100
   B. Market Analytics.....II-60
Table 12: Canadian Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-60
1$350
   Table 13: Canadian Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-611$350
   A. Market Analysis.....II-62
Current & Future Analysis.....II-62
Clinical Trials.....II-62
1$100
   B. Market Analytics.....II-63
Table 14: European Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology by Region/Country - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-63
1$350
   Table 15: European Historic Review for Apoptosis Modulators in Oncology by Region/Country - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-641$350
   Table 16: European 15-Year Perspective For Apoptosis Modulators in Oncology by Region/Country - Percentage Breakdown of Revenue for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart).....II-651$350
   A. Market Analysis.....II-66
Current & Future Analysis.....II-66
Theraptosis SA – A Key French Player.....II-66
1$100
   B. Market Analytics.....II-67
Table 17: French Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-67
1$350
   Table 18: French Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-681$350
   A. Market Analysis.....II-69
Current & Future Analysis.....II-69
Æterna Zentaris GmbH - A Key German Player.....II-69
1$100
   B. Market Analytics.....II-70
Table 19: German Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-70
1$350
   Table 20: German Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-711$350
   A. Market Analysis.....II-72
Current & Future Analysis.....II-72
Genextra S.p.A. – A Key Italian Player.....II-72
1$100
   B. Market Analytics.....II-73
Table 21: Italian Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-73
1$350
   Table 22: Italian Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-741$350
   A. Market Analysis.....II-75
Current & Future Analysis.....II-75
Recent Industry Activity.....II-75
Key Players.....II-75
1$100
   B. Market Analytics.....II-76
Table 23: UK Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-76
1$350
   Table 24: UK Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-771$350
   Market Analysis.....II-78
Table 25: Spanish Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-78
1$350
   Table 26: Spanish Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-791$350
   A. Market Analysis.....II-80
Current & Future Analysis.....II-80
Key Players.....II-80
1$100
   B. Market Analytics.....II-81
Table 27: Rest of Europe Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-81
1$350
   Table 28: Rest of Europe Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-821$350
   A. Market Analysis.....II-83
Current & Future Analysis.....II-83
Clinical Trials.....II-83
Recent Industry Activity.....II-83
1$100
   Key Player.....II-841$100
   B. Market Analytics.....II-85
Table 29: Asia-Pacific Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-85
1$350
   Table 30: Asia-Pacific Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-861$350
   A. Market Analysis.....II-87
Current & Future Analysis.....II-87
Recent Industry Activity.....II-87
1$100
   B. Market Analytics.....II-88
Table 31: Latin America Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-88
1$350
   Table 32: Latin America Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-891$350
   A. Market Analysis.....II-90
Current & Future Analysis.....II-90
Clinical Trials.....II-90
Recent Industry Activity.....II-90
1$100
   B. Market Analytics.....II-91
Table 33: Rest of World Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-91
1$350
   Table 34: Rest of World Historic Review for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-921$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com